Saranya Chumsri, MD
Enriched profileProfessor of Oncology, Mayo Clinic · Mayo Clinic in Florida
Saranya Chumsri is Professor of Oncology, Mayo Clinic at Mayo Clinic in Florida. OpenAlex indexes 389 publications with 5,205 citations (h-index 37); ClinicalTrials.gov lists 17 registered studies with this person as an investigator.
Data verified 23 Oct 2026
Overview
Updated 24 Oct 2026
Saranya Chumsri, MD, is Professor of Oncology, Mayo Clinic at Mayo Clinic in Florida (Jacksonville, FL). The public record shows 389 publications with 5,205 citations (h-index 37), centered on Breast Cancer Treatment Studies, Cancer Immunotherapy and Biomarkers, HER2/EGFR in Cancer Research. It also documents an investigator role on 17 registered clinical trials, industry payments reported by 14 companies.
- Most recent indexed publication: 2026 · Cancers
- Top research focus: Breast Cancer Treatment Studies
- 17 registered trials on ClinicalTrials.gov
- Open Payments reporting from 14 companies
Generated from the cited public record · current as of 24 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 10 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 70.
Clinical & industry
trials, payments and federal fundingFederally funded research awards.
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 24 Oct 2026
Listed as an investigator on 17 registered studies on ClinicalTrials.gov. The most recent:
- ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab
Sponsor: Alliance for Clinical Trials in Oncology
Industry payments
Updated 24 Oct 2026
14 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Merck Sharp & Dohme LLCProgram year20254 payments
- Stemline Therapeutics Inc.Program year20252 payments
- PFIZER INC.Program year20251 payment
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
61.9%Aromatase Inhibitor46.2%Letrozole66%Anastrozole25%Exemestane10%Part D≥75 patientsKinase inhibitor13.8%Verzenio57%Kisqali25%Tukysa18%Part D<11 patients+ 1 more class in this area
Sensory organs
18.4%Corticosteroid18.4%Dexamethasone sodium phosphate90%Dexamethasone10%Part D + Part B<11 patientsNervous system
11.8%Opioid Agonist5.7%Oxycodone Hcl72%Oxycontin28%Part D<11 patientsGabapentinoids2.1%Gabapentin100%Part D<11 patients+ 2 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →
Congress activity
Updated 24 Oct 2026
171 congress contributions (2008–2026) across AACR, ASCO, ASTRO, ESMO, SABCS per OpenAlex. The most recent:
- Abstract 1065: Mitosis in circulating tumor cells correlates with highly aggressive disease in metastatic breast cancer
AACR Annual Meeting
AACR2026Co-author - Abstract 1200: Spatially resolved tumor-cell MHC class II shapes adaptive immunity and therapeutic response in triple-negative breast cancer.
AACR Annual Meeting
AACR2026Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 24 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Advancing the Oncology Data Paradigm: Multisite Expansion of Structured Cancer Data Capture at the Point of Care.
JCO oncology practice
Article2026 - Characterization of Oncogenic and Immunogenic Profiling in Patients with Breast Cancer Tumors After Radiation Therapy.
International journal of molecular sciences
Article2026 - Pembrolizumab in Combination with Binimetinib in Patients with Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer.
Clinical cancer research
Clinical Trial2025
Most-cited works
by citation count (OpenAlex)- 01Next generation of immune checkpoint therapy in cancer: new developments and challengesArticle805 citations2018
- 02Aromatase, aromatase inhibitors, and breast cancerArticle400 citations2011
- 03Circulating giant macrophages as a potential biomarker of solid tumorsArticle272 citations2014
- 04
- 05Increasing National Mastectomy Rates for the Treatment of Early Stage Breast CancerArticle195 citations2012
Network
Updated 24 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 24 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/saranya-chumsri-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 24 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mayoclinic.org ↗
- M.D.
Chulalongkorn University
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mayoclinic.org ↗
Editorial & leadership roles
journal and society appointments- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mayoclinic.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mayoclinic.org ↗
- Co-chair
Breast Disease Group, Mayo Clinic Comprehensive Cancer Center
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mayo.edu ↗ - Chair
HER2-Positive Working Group, Mayo Clinic Comprehensive Cancer Center
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mayo.edu ↗ - Steering committee member
(Neo)ALTTO
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mayoclinic.org ↗ - Member
Breast Cancer Committee, Academic and Community Cancer Research United Consortium
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mayoclinic.org ↗ - Member
Immuno-Oncology Committee, Alliance for Clinical Trials in Oncology
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mayoclinic.org ↗ - Clinician-scientist reviewer
Breast Cancer Research Program (Department of Defense)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →ibegin.com ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mayoclinic.org ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →mayoclinic.org ↗
Secondary affiliations
appointments beyond the home institution- Joint appointment
Department of Cancer Biology (Mayo Clinic)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →mayo.edu ↗
Media & interviews
press, podcasts and appearances- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →inthenews.mayoclinic.org ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Thomas Brott, MD
Mayo Clinic in Florida
Roxana Dronca, MD
Mayo Clinic in Florida
Keith Oken, MD
Mayo Clinic in Florida
Ruqin Chen, MD
Mayo Clinic in Florida
Gabriel Hortobagyi, MD
The University of Texas MD Anderson Cancer Center
Eric Winer, MD
Yale School of Medicine
Norman Wolmark, MD
University of Pittsburgh
Hope Rugo, MD
City of Hope